Therapeutic Plasma Exchange: For Cancer Patients

References

• Kuang W, Tan J, Yuan X, et al. Plasma exchange therapy holds promise in the management of advanced cancer. Med Hypotheses. 2009;72(5):533–534. doi:10.1016/j.mehy.2008.11.030
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev. 2020;86:102019. doi:10.1016/j.ctrv.2020.102019
   PubMed Web of Science ®Google Scholar
• Clark WF, Huang SS. Introduction to therapeutic plasma exchange. Transfus Apher Sci. 2019;58(3):228–229. doi:10.1016/j.transci.2019.04.004
   PubMed Web of Science ®Google Scholar
• Tiwari AK, Bhardwaj G, Aggarwal G, et al. Changing trends in therapeutic plasmapheresis: an Indian perspective. Ther Apher Dial. 2017;21(5):500–506. doi:10.1111/1744-9987.12549
   PubMed Web of Science ®Google Scholar
• Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF. A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2007;17(1):17–35. doi:10.1111/j.1365-3148.2006.00720.x
   PubMed Web of Science ®Google Scholar
• Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335. doi:10.1111/j.1365-2141.2012.09167.x
   PubMed Web of Science ®Google Scholar
• Ahmadpoor P, Aglae C, Cariou S, et al. Physiological role of plasma and its components and the clinical implications of different methods of apheresis: a narrative review. Ther Apher Dial. 2021;25(3):262–272. doi:10.1111/1744-9987.13567
   PubMed Web of Science ®Google Scholar
• Connelly-Smith LS, Linenberger ML. Therapeutic apheresis for patients with cancer. Cancer Control. 2015;22(1):60–78. doi:10.1177/107327481502200109
   PubMed Web of Science ®Google Scholar
• Dumas G, Merceron S, Zafrani L, et al. [Hyperviscosity syndrome]. Rev Med Interne. 2015;36(9):588–595. French. doi:10.1016/j.revmed.2015.02.005
   PubMed Web of Science ®Google Scholar
• Perez Rogers A, Estes M. Hyperviscosity Syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
   Google Scholar
• Higdon ML, Atkinson CJ, Lawrence KV. Oncologic emergencies: recognition and initial management. Am Fam Physician. 2018;97(11):741–748.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol. 2014;18(1):41–49. doi:10.1007/s10157-013-0838-0
   PubMed Web of Science ®Google Scholar
• Hirano R, Namazuda K, Suemitsu J, Harashima T, Hirata N. Plasma separation using a membrane. Transfus Apher Sci. 2017;56(5):649–653. doi:10.1016/j.transci.2017.08.008
   PubMed Web of Science ®Google Scholar
• Mineshima M. Double filtration plasmapheresis: determination of the optimal albumin concentration in the supplementation fluid. Transfus Apher Sci. 2017;56(5):654–656. doi:10.1016/j.transci.2017.08.009
   PubMed Web of Science ®Google Scholar
• Ogawa T, Yoshino H, Sasaki Y, et al. Our approaches to selective plasma exchange. Contrib Nephrol. 2018;196:194–199.
   PubMed Web of Science ®Google Scholar
• Zanatta E, Cozzi M, Marson P, Cozzi F. The role of plasma exchange in the management of autoimmune disorders. Br J Haematol. 2019;186(2):207–219. doi:10.1111/bjh.15903
   PubMed Web of Science ®Google Scholar
• McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19(1):157–167. doi:10.1016/j.beha.2005.01.004
   PubMed Web of Science ®Google Scholar
• Yeh JH, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol. 2000;247(7):510–513. doi:10.1007/s004150070149
   PubMed Web of Science ®Google Scholar
• Chauvel F, Reboul P, Cariou S, et al. Use of double filtration plasmapheresis for the treatment of acquired thrombocytopenic thrombotic purpura. Ther Apher Dial. 2020;24(6):709–717. doi:10.1111/1744-9987.13477
   PubMed Web of Science ®Google Scholar
• Higashihara T, Kawase M, Kobayashi M, et al. Evaluating the efficacy of double-filtration plasmapheresis in treating five patients with drug-resistant pemphigus. Ther Apher Dial. 2017;21(3):243–247. doi:10.1111/1744-9987.12557
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu J, Wang H, et al. Double filtration plasmapheresis benefits myasthenia gravis patients through an immunomodulatory action. J Clin Neurosci. 2014;21(9):1570–1574. doi:10.1016/j.jocn.2013.11.046
   PubMed Web of Science ®Google Scholar
• Onohara T, Sakamoto Y, Inoue S. Plasma adsorption membranes are able to efficiently remove high mobility group box-1 (HMGB-1). J Nippon Med Sch. 2018;85(3):150–156. doi:10.1272/jnms.JNMS.2018_85-22
   PubMed Web of Science ®Google Scholar
• Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Ther Apher Dial. 2003;7(1):85–90. doi:10.1046/j.1526-0968.2003.00010.x
   PubMed Web of Science ®Google Scholar
• Hirano R, Hirata N. Immunoadsorption using Immusorba TR and PH. Transfus Apher Sci. 2017;56(5):661–665. doi:10.1016/j.transci.2017.08.011
   PubMed Web of Science ®Google Scholar
• Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;2014(9):Cd002063.
   PubMedGoogle Scholar
• Galldiks N, Burghaus L, Dohmen C, et al. Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment. Eur Neurol. 2011;66(4):183–189. doi:10.1159/000331011
   PubMed Web of Science ®Google Scholar
• Schimrigk S, Faiss J, Köhler W, et al. Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunoadsorption - observational multicenter study with 147 patients. Eur Neurol. 2016;75(5–6):300–306. doi:10.1159/000447059
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Nanri K, Taguchi T, et al. Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase. J Clin Apher. 2015;30(1):43–45. doi:10.1002/jca.21324
   PubMed Web of Science ®Google Scholar
• Loo CY, Mohamed Said MS, Mohd R, et al. Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci. 2010;43(3):335–340. doi:10.1016/j.transci.2010.10.003
   PubMed Web of Science ®Google Scholar
• Baggi F, Ubiali F, Nava S, et al. Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. J Neuroimmunol. 2008;201–202:104–110. doi:10.1016/j.jneuroim.2008.05.026
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354. doi:10.1002/jca.21705
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175–181. doi:10.1034/j.1600-0609.2000.90221.x
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008;22(8):1485–1493. doi:10.1038/leu.2008.131
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosiñol L. Renal, hematologic and infectious complications in multiple myeloma. Best Pract Res Clin Haematol. 2005;18(4):635–652. doi:10.1016/j.beha.2005.01.013
   PubMed Web of Science ®Google Scholar
• Defronzo RA, Humphrey RL, Wright JR, Cooke CR. Acute renal failure in multiple myeloma. Medicine (Baltimore). 1975;54(3):209–223. doi:10.1097/00005792-197505000-00003
   PubMed Web of Science ®Google Scholar
• Feest TG, Burge PS, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. Br Med J. 1976;1(6008):503–504. doi:10.1136/bmj.1.6008.503
   PubMed Web of Science ®Google Scholar
• Johnson WJ, Kyle RA, Pineda AA, O’Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990;150(4):863–869. doi:10.1001/archinte.1990.00390160111022
   PubMedGoogle Scholar
• Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33(6):1175–1180. doi:10.1038/ki.1988.127
   PubMed Web of Science ®Google Scholar
• Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143(11):777–784. doi:10.7326/0003-4819-143-11-200512060-00005
   PubMed Web of Science ®Google Scholar
• Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73(11):1282–1288. doi:10.1038/ki.2008.108
   PubMed Web of Science ®Google Scholar
• Yu X, Gan L, Wang Z, Dong B, Chen X. Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis. Int J Clin Pharmacol Ther. 2015;53(5):391–397. doi:10.5414/CP202245
   PubMed Web of Science ®Google Scholar
• Madore F. Does plasmapheresis have a role in the management of myeloma cast nephropathy? Nat Clin Pract Nephrol. 2006;2(8):406–407. doi:10.1038/ncpneph0229
   PubMedGoogle Scholar
• Leung N. Plasma exchange in multiple myeloma. Ann Intern Med. 2006;144(6):455; author reply 455. doi:10.7326/0003-4819-144-6-200603210-00021
   PubMed Web of Science ®Google Scholar
• Chapdelaine I, Madore F. Plasmapheresis in myeloma cast nephropathy. Clin Nephrol. 2013;79(1):72–77. doi:10.5414/CN107064
   PubMed Web of Science ®Google Scholar
• Premuzic V, Batinic J, Roncevic P, Basic-Jukic N, Nemet D, Jelakovic B. Role of plasmapheresis in the management of acute kidney injury in patients with multiple myeloma: should we abandon it? Ther Apher Dial. 2018;22(1):79–86. doi:10.1111/1744-9987.12606
   PubMed Web of Science ®Google Scholar
• Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2015;15(4):187–198. doi:10.1016/j.clml.2014.09.012
   PubMed Web of Science ®Google Scholar
• Fabbrini P, Finkel K, Gallieni M, et al. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. J Nephrol. 2016;29(6):735–746. doi:10.1007/s40620-016-0347-9
   PubMed Web of Science ®Google Scholar
• Stone MJ. Waldenström’s macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):97–99. doi:10.3816/CLM.2009.n.026
   PubMedGoogle Scholar
• Ballestri M, Ferrari F, Magistroni R, et al. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Ann Ist Super Sanita. 2007;43(2):171–175.
   PubMedGoogle Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012;10(10):1211–1219. doi:10.6004/jnccn.2012.0128
   PubMed Web of Science ®Google Scholar
• Fahey JL, Barth WF, Solomon A. Serum hyperviscosity syndrome. JAMA. 1965;192:464–467. doi:10.1001/jama.1965.03080190030008
   PubMed Web of Science ®Google Scholar
• Kwaan HC. Hyperviscosity in plasma cell dyscrasias. Clin Hemorheol Microcirc. 2013;55(1):75–83. doi:10.3233/CH-131691
   PubMed Web of Science ®Google Scholar
• Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):211–215. doi:10.1053/sonc.2003.50064
   PubMed Web of Science ®Google Scholar
• Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012;118(15):3793–3800. doi:10.1002/cncr.26627
   PubMed Web of Science ®Google Scholar
•  French AI. [Management of splenectomized or sickle cell anemia patients in city medicine]. Presse Med. 2003;32(28 Suppl):S31–34. French.
   PubMed Web of Science ®Google Scholar
• Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2009;114(12):2375–2385. doi:10.1182/blood-2009-05-174359
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2012;119(10):2205–2208. doi:10.1182/blood-2011-04-347690
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Role of plasmapheresis in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013;13(2):238–240. doi:10.1016/j.clml.2013.02.013
   PubMed Web of Science ®Google Scholar
• Tsujita Y, Imai K, Honma K, Kamae C, Horiuchi T, Nonoyama S. A severe anaphylactic reaction associated with IgM-class anti-human IgG antibodies in a hyper-IgM syndrome type 2 patient. J Clin Immunol. 2018;38(1):144–148. doi:10.1007/s10875-017-0466-7
   PubMed Web of Science ®Google Scholar
• Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12325-017-0612-x
   PubMed Web of Science ®Google Scholar
• Stone MJ, Pascual V. Pathophysiology of Waldenström’s macroglobulinemia. Haematologica. 2010;95(3):359–364. doi:10.3324/haematol.2009.017251
   PubMed Web of Science ®Google Scholar
• Müllges W, Stoll G. [Myasthenia gravis]. Nervenarzt. 2019;90(10):1055–1066. German. doi:10.1007/s00115-019-00798-8
   PubMed Web of Science ®Google Scholar
• Zieliński M. Management of myasthenic patients with thymoma. Thorac Surg Clin. 2011;21(1):47–57, vi. doi:10.1016/j.thorsurg.2010.08.009
   PubMed Web of Science ®Google Scholar
• Jani-Acsadi A, Lisak RP. Myasthenia gravis. Curr Treat Options Neurol. 2010;12(3):231–243. doi:10.1007/s11940-010-0070-0
   PubMed Web of Science ®Google Scholar
• Querol L, Illa I. Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol. 2013;26(5):459–465. doi:10.1097/WCO.0b013e328364c079
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. doi:10.1016/S1474-4422(15)00145-3
   PubMed Web of Science ®Google Scholar
• Nguyen-Cao TM, Gelinas D, Griffin R, Mondou E. Myasthenia gravis: historical achievements and the “golden age” of clinical trials. J Neurol Sci. 2019;406:116428. doi:10.1016/j.jns.2019.116428
   PubMed Web of Science ®Google Scholar
• Mandawat A, Mandawat A, Kaminski HJ, Shaker ZA, Alawi AA, Alshekhlee A. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 2011;43(4):578–584. doi:10.1002/mus.21924
   PubMed Web of Science ®Google Scholar
• Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M. Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial. J Neurol. 2007;254(8):989–995. doi:10.1007/s00415-006-0235-7
   PubMed Web of Science ®Google Scholar
• Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22(3):509–526. doi:10.1016/j.hoc.2008.03.004
   PubMed Web of Science ®Google Scholar
• Blichfeldt-Lauridsen L, Hansen BD. Anesthesia and myasthenia gravis. Acta Anaesthesiol Scand. 2012;56(1):17–22. doi:10.1111/j.1399-6576.2011.02558.x
   PubMed Web of Science ®Google Scholar
• Reis TA, Cataneo DC, Cataneo AJM. Clinical usefulness of prethymectomy plasmapheresis in patients with myasthenia gravis: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2019;29(6):867–875. doi:10.1093/icvts/ivz186
   PubMed Web of Science ®Google Scholar
• Köhler W, Bucka C, Klingel R. A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis. J Clin Apher. 2011;26(6):347–355. doi:10.1002/jca.20317
   PubMed Web of Science ®Google Scholar
• Ströbel P, Preisshofen T, Helmreich M, Müller-Hermelink HK, Marx A. Pathomechanisms of paraneoplastic myasthenia gravis. Clin Dev Immunol. 2003;10(1):7–12. doi:10.1080/10446670310001598528
   PubMedGoogle Scholar
• Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur J Neurol. 2009;16(12):1318–1322. doi:10.1111/j.1468-1331.2009.02729.x
   PubMed Web of Science ®Google Scholar
• Liu JF, Wang WX, Xue J, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial. 2010;14(2):153–160. doi:10.1111/j.1744-9987.2009.00751.x
   PubMed Web of Science ®Google Scholar
• Jiang W, Yu Q. Case report of thymoma tumor reduction following plasmapheresis. Medicine (Baltimore). 2015;94(47):e2173. doi:10.1097/MD.0000000000002173
   PubMed Web of Science ®Google Scholar
• Munakata R, Utsugisawa K, Nagane Y, et al. The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis. Eur Neurol. 2002;48(2):115–117. doi:10.1159/000062987
   PubMed Web of Science ®Google Scholar
• Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y. Efficacy of low-dose FK506 in the treatment of Myasthenia gravis–a randomized pilot study. Eur Neurol. 2005;53(3):146–150. doi:10.1159/000085833
   PubMed Web of Science ®Google Scholar
• Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–1554. doi:10.1056/NEJMra023009
   PubMed Web of Science ®Google Scholar
• Vernino S, O’Neill BP, Marks RS, O’Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55–62. doi:10.1215/S1152851703000395
   PubMed Web of Science ®Google Scholar
• Blaes F. Paraneoplastic neurological syndromes–diagnosis and management. Curr Pharm Des. 2012;18(29):4518–4525. doi:10.2174/138161212802502323
   PubMed Web of Science ®Google Scholar
• Sculier C, Bentea G, Ruelle L, et al. Autoimmune paraneoplastic syndromes associated to lung cancer: a systematic review of the literature: part 5: neurological auto-antibodies, discussion, flow chart, conclusions. Lung Cancer. 2017;111:164–175. doi:10.1016/j.lungcan.2017.07.026
   PubMed Web of Science ®Google Scholar
• Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27(6):489–495. doi:10.1097/CCO.0000000000000222
   PubMed Web of Science ®Google Scholar
• Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol. 2013;15(2):185–200. doi:10.1007/s11940-012-0215-4
   PubMed Web of Science ®Google Scholar
• Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Expert Opin Biol Ther. 2002;2(4):419–430. doi:10.1517/14712598.2.4.419
   PubMed Web of Science ®Google Scholar
• Bradley WH, Dottino PR, Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. Int J Gynecol Cancer. 2008;18(6):1364–1367. doi:10.1111/j.1525-1438.2007.01173.x
   PubMed Web of Science ®Google Scholar
• Antoine JC, Mosnier JF, Absi L, Convers P, Honnorat J, Michel D. Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies. J Neurol Neurosurg Psychiatry. 1999;67(1):7–14. doi:10.1136/jnnp.67.1.7
   PubMed Web of Science ®Google Scholar
• Tschernatsch M, Stolz E, Strittmatter M, Kaps M, Blaes F. Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data. J Neurol Neurosurg Psychiatry. 2005;76(12):1702–1706. doi:10.1136/jnnp.2003.033225
   PubMed Web of Science ®Google Scholar
• Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol. 2014;175(3):336–348. doi:10.1111/cei.12185
   PubMed Web of Science ®Google Scholar
• van Broekhoven F, de Graaf MT, Bromberg JE, et al. Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2010;81(12):1341–1344. doi:10.1136/jnnp.2009.177865
   PubMed Web of Science ®Google Scholar
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2011(2):Cd003279.
   PubMedGoogle Scholar
• Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–1107. doi:10.1016/S1474-4422(11)70245-9
   PubMed Web of Science ®Google Scholar
• Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome. Neurology. 2020;94(5):e511–e520. doi:10.1212/WNL.0000000000008747
   PubMed Web of Science ®Google Scholar
• Tarr TB, Wipf P, Meriney SD. Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome. Mol Neurobiol. 2015;52(1):456–463. doi:10.1007/s12035-014-8887-2
   PubMed Web of Science ®Google Scholar
• Bekircan-Kurt CE, Derle Çiftçi E, Kurne AT, Anlar B. Voltage gated calcium channel antibody-related neurological diseases. World J Clin Cases. 2015;3(3):293–300. doi:10.12998/wjcc.v3.i3.293
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: baseline demographics and treatment approaches. Neurol Ther. 2015;4(2):105–124. doi:10.1007/s40120-015-0034-0
   PubMedGoogle Scholar
• Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006;63(8):1066–1071. doi:10.1001/archneur.63.8.1066
   PubMedGoogle Scholar
• Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984;34(4):480–485. doi:10.1212/WNL.34.4.480
   PubMed Web of Science ®Google Scholar
• Lang B, Newsom-Davis J, Wray D, Vincent A, Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981;2(8240):224–226. doi:10.1016/S0140-6736(81)90474-8
   PubMed Web of Science ®Google Scholar
• Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;58(4):594–604. doi:10.1002/ana.20614
   PubMed Web of Science ®Google Scholar
• Mathis S, Pin JC, Pierre F, et al. Anti-NMDA receptor encephalitis during pregnancy: a case report. Medicine (Baltimore). 2015;94(26):e1034. doi:10.1097/MD.0000000000001034
   PubMed Web of Science ®Google Scholar
• Mann AP, Grebenciucova E, Lukas RV. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Ther Clin Risk Manag. 2014;10:517–525. doi:10.2147/TCRM.S61967
   PubMed Web of Science ®Google Scholar
• DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher. 2015;30(4):212–216. doi:10.1002/jca.21363
   PubMed Web of Science ®Google Scholar
• Chourasia N, Watkins MW, Lankford JE, Kass JS, Kamdar A. An infant born to a mother with anti-N-methyl-d-aspartate receptor encephalitis. Pediatr Neurol. 2018;79:65–68. doi:10.1016/j.pediatrneurol.2017.11.010
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013;81(12):1058–1063. doi:10.1212/WNL.0b013e3182a4a49c
   PubMed Web of Science ®Google Scholar
• Lamale-Smith LM, Moore GS, Guntupalli SR, Scott JB. Maternal-fetal transfer of anti-N-methyl-D-aspartate receptor antibodies. Obstet Gynecol. 2015;125(5):1056–1058. doi:10.1097/AOG.0000000000000548
   PubMed Web of Science ®Google Scholar
• Altintas A, Dargvainiene J, Schneider-Gold C, et al. Gender issues of antibody-mediated diseases in neurology: (NMOSD/autoimmune encephalitis/MG). Ther Adv Neurol Disord. 2020;13:1756286420949808. doi:10.1177/1756286420949808
   Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in toxicological research of the anticancer drug cisplatin. Chem Res Toxicol. 2019;32(8):1469–1486. doi:10.1021/acs.chemrestox.9b00204
   PubMed Web of Science ®Google Scholar
• Perše M. Cisplatin mouse models: treatment, toxicity and translatability. Biomedicines. 2021;9(10):1406. doi:10.3390/biomedicines9101406
   PubMed Web of Science ®Google Scholar
• Murata S, Onozawa S, Oda T, et al. Pharmacologic advantages of negative-balance isolated pelvic perfusion: achievement of intensive exposure of the pelvis to platinum without systemic leakage. Radiology. 2012;262(2):503–510. doi:10.1148/radiol.11102453
   PubMed Web of Science ®Google Scholar
• Reeves HM, Winters JL. The mechanisms of action of plasma exchange. Br J Haematol. 2014;164(3):342–351. doi:10.1111/bjh.12629
   PubMed Web of Science ®Google Scholar
• Charlier C, Kintz P, Dubois N, Plomteux G. Fatal overdosage with cisplatin. J Anal Toxicol. 2004;28(2):138–140. doi:10.1093/jat/28.2.138
   PubMed Web of Science ®Google Scholar
• Jung HK, Lee J, Lee SN. A case of massive cisplatin overdose managed by plasmapheresis. Korean J Intern Med. 1995;10(2):150–154. doi:10.3904/kjim.1995.10.2.150
   PubMedGoogle Scholar
• Chu G, Mantin R, Shen YM, Baskett G, Sussman H. Massive cisplatin overdose by accidental substitution for carboplatin. Toxicity and management. Cancer. 1993;72(12):3707–3714. doi:10.1002/1097-0142(19931215)72:12<3707::AID-CNCR2820721224>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Choi JH, Oh JC, Kim KH, Chong SY, Kang MS, Oh DY. Successful treatment of cisplatin overdose with plasma exchange. Yonsei Med J. 2002;43(1):128–132. doi:10.3349/ymj.2002.43.1.128
   PubMed Web of Science ®Google Scholar
• Hofmann G, Bauernhofer T, Krippl P, et al. Plasmapheresis reverses all side-effects of a cisplatin overdose–a case report and treatment recommendation. BMC Cancer. 2006;6:1. doi:10.1186/1471-2407-6-1
   PubMed Web of Science ®Google Scholar
• Yamada Y, Ikuta Y, Nosaka K, et al. Successful treatment of Cisplatin overdose with plasma exchange. Case Rep Med. 2010;2010:802312. doi:10.1155/2010/802312
   PubMedGoogle Scholar
• Emir S, Özyörük D, Arman Ö, Özbek N, Tunç B. Accidental cisplatin overdose in a child: successful management with repetitive plasmapheresis and use of chemoprotective agents. Turk J Pediatr. 2016;58(3):315–317. doi:10.24953/turkjped.2016.03.015
   PubMed Web of Science ®Google Scholar
• Chegini A, Moghadami M, Maghary AH. Therapeutic plasma exchange in Tehran between 2011 and 2014. Ther Apher Dial. 2020;24(2):230–234. doi:10.1111/1744-9987.12864
   PubMed Web of Science ®Google Scholar
• Mörtzell Henriksson M, Newman E, Witt V, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2–15. doi:10.1016/j.transci.2016.01.003
   PubMed Web of Science ®Google Scholar
• Lu J, Zhang L, Xia C, Tao Y. Complications of therapeutic plasma exchange: a retrospective study of 1201 procedures in 435 children. Medicine (Baltimore). 2019;98(50):e18308. doi:10.1097/MD.0000000000018308
   PubMed Web of Science ®Google Scholar
• Kaplan A. Complications of apheresis. Semin Dial. 2012;25(2):152–158. doi:10.1111/j.1525-139X.2011.01026.x
   PubMed Web of Science ®Google Scholar
• Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z. Complications of therapeutic plasma exchange: experience with 4857 treatments. Ther Apher Dial. 2005;9(5):391–395. doi:10.1111/j.1744-9987.2005.00319.x
   PubMed Web of Science ®Google Scholar
• Bramlage CP, Schröder K, Bramlage P, et al. Predictors of complications in therapeutic plasma exchange. J Clin Apher. 2009;24(6):225–231. doi:10.1002/jca.20217
   PubMed Web of Science ®Google Scholar
• McLeod BC. Plasma and plasma derivatives in therapeutic plasmapheresis. Transfusion. 2012;52(Suppl 1):38s–44s. doi:10.1111/j.1537-2995.2012.03623.x
   PubMed Web of Science ®Google Scholar
• Yeh JH, Chen WH, Chiu HC. Complications of double-filtration plasmapheresis. Transfusion. 2004;44(11):1621–1625. doi:10.1111/j.1537-2995.2004.04154.x
   PubMed Web of Science ®Google Scholar
• Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: incidence and relative frequency. Asian J Transfus Sci. 2013;7(1):37–41. doi:10.4103/0973-6247.106730
   PubMedGoogle Scholar
• Momtaz M, Fayed A, Marzouk K, Shaker A. Therapeutic plasma exchange outcomes in Cairo university hospitals: 6 years experience. Ther Apher Dial. 2018;22(6):666–673. doi:10.1111/1744-9987.12710
   PubMed Web of Science ®Google Scholar
• Mineshima M, Akiba T. Double filtration plasmapheresis in critical care. Ther Apher Dial. 2002;6(3):180–183. doi:10.1046/j.1526-0968.2002.00428.x
   Web of Science ®Google Scholar
• Jouve T, Marlu R, Malvezzi P, et al. Reducing fibrinogen and factor XIII using double-filtration plasmapheresis for antibody-mediated rejection: predictive models. Blood Purif. 2018;46(3):239–245. doi:10.1159/000488928
   PubMed Web of Science ®Google Scholar
• Zöllner S, Pablik E, Druml W, Derfler K, Rees A, Biesenbach P. Fibrinogen reduction and bleeding complications in plasma exchange, immunoadsorption and a combination of the two. Blood Purif. 2014;38(2):160–166. doi:10.1159/000367682
   PubMed Web of Science ®Google Scholar
• Oji S, Nomura K. Immunoadsorption in neurological disorders. Transfus Apher Sci. 2017;56(5):671–676. doi:10.1016/j.transci.2017.08.013
   PubMed Web of Science ®Google Scholar
• Koessler J, Kobsar A, Kuhn S, et al. The effect of immunoadsorption with the immusorba TR-350 column on coagulation compared to plasma exchange. Vox Sang. 2015;108(1):46–51. doi:10.1111/vox.12191
   PubMed Web of Science ®Google Scholar
• Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1727 procedures. J Clin Apher. 2007;22(5):270–276. doi:10.1002/jca.20143
   PubMed Web of Science ®Google Scholar